Chúng ta đang ở đâu trong kỷ nguyên điều trị theo mục tiêu? Các yếu tố dự đoán cho tình trạng thuyên giảm và chuyển đổi thuốc ở bệnh nhân viêm cột sống dính khớp trục: Chứng cứ thực tế từ đăng ký quốc gia BioStaR

Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D (2019) A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 71:1101-1111.: https://doi.org/10.1002/art.40866 Rodrigues-Manica S, Silva J, Cruz-Machado R, Coelho C, Duarte J, Vieira-Sousa E, Tavares-Costa J, Pimentel-Santos FM (2021) Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action. Clin Rheumatol 40:33–41. https://doi.org/10.1007/s10067-020-05209-x Sieper J, Landewé R, Magrey M, Anderson JK, Zhong S, Wang X, Lertratanakul A (2019) Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open. 7;5:e000917.: https://doi.org/10.1136/rmdopen-2019-000917 Shimabuco AY, Gonçalves CR, Moraes JCB, Waisberg MG, Ribeiro ACM, Sampaio-Barros PD, Goldenstein-Schainberg C, Bonfa E, Saad CGS (2018) Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors. Adv Rheumatol. 4;58:40.: https://doi.org/10.1186/s42358-018-0040-x Chen X, Zhang T, Wang W, Xue J (2018) Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission. Clin Rheumatol 37:1625–1632. https://doi.org/10.1007/s10067-018-4084-4 Pradeep DJ, Keat AC, Gaffney K, Brooksby A, Leeder J, Harris C (2008) Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford) 47:1726–1727. https://doi.org/10.1093/rheumatology/ken334 Haberhauer G, Strehblow C, Fasching P (2010) Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr 160:220–4. https://doi.org/10.1007/s10354-010-0795-0 Monti S, Todoerti M, Codullo V, Favalli EG, Biggioggero M, Becciolini A, Montecucco C, Caporali R (2018) Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Mod Rheumatol 28:542–549. https://doi.org/10.1080/14397595.2017.1367076 Landewé R, van Tubergen A (2015) Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep. 17:47.:https://doi.org/10.1007/s11926-015-0522-3 Machado PM, Deodhar A (2019). Treat-to-target in axial spondyloarthritis: gold standard or fools’ gold? Curr Opin Rheumatol. 31:344–348.:https://doi.org/10.1097/BOR.0000000000000625 Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, Clegg DO, Colbert RA, Gensler LS, van der Heijde D, van der Horst-Bruinsma IE, Inman RD, Maksymowych WP, Mease PJ, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, Weisman MH, Landewé RB (2014) The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration’s comments and concerns. Arthritis Rheumatol. 66:2649–2656.:https://doi.org/10.1002/art.38776 Poddubnyy D, Gensler LS (2014) Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 28:807–818. https://doi.org/10.1016/j.berh.2014.10.005 Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, Martínez-Feito A, Jochems A, Kneepkens EL, Wolbink GJ, Rispens T, Diego C, Pascual-Salcedo D, Balsa A (2019) Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. Arthritis Res Ther. 211:66.:https://doi.org/10.1186/s13075-019-1849-3 Carvalho PD, Ruyssen-Witrand A, Fonseca J, Marreiros A, Machado PM (2020) Determining factors related to impaired spinal and hip mobility in patients with axial spondyloarthritis: longitudinal results from the DESIR cohort. RMD Open. 6:e001356.:https://doi.org/10.1136/rmdopen-2020-001356 Akgul O, Bodur H, Ataman S, Yurdakul FG, Capkin E, Gurer G, Sezer I, Duruoz MT, Melikoglu MA, Cay HF, Rezvani A, Yagci I, Gogus F, Kamanli A, Cevik R (2020) Clinical performance of ASAS Health Index in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry. Rheumatol Int. 40:1793–1801.:https://doi.org/10.1007/s00296-020-04680-8 Landewé RB, van der Heijde D, Dougados M, Baraliakos X, Van den Bosch FE, Gaffney K, Bauer L, Hoepken B, Davies OR, de Peyrecave N, Thomas K, Gensler LS (2020) Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis. 79:920–928.:https://doi.org/10.1136/annrheumdis-2019-216839 Landewé R, van der Heijde D, Dougados M, Baraliakos X, Van den Bosch F, Gaffney K, Bauer L, Hoepken B, de Peyrecave N, Thomas K, Gensler LS (2020) Induction of sustained clinical remission in early axial spondyloarthritis following certolizumabpegol treatment: 48-week outcomes from C-OPTIMISE. Rheumatol Ther. 7:581–599.: https://doi.org/10.1007/s40744-020-00214-7. Lubrano E, Perrotta FM, Marchesoni A, D’Angelo S, Ramonda R, Addimanda O et al (2015) Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-a drugs: an Italian multicenter study. J Rheumatol 42:258–263 van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA et al (2014) The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol 41:1095–1103 Zochling J, Braun J (2006) Remission in ankylosing spondylitis. Clin Exp Rheumatol. 24:S-88–92. Ziade N, Abi Karam G, Merheb G, Mallak I, Irani L, Alam E, Messaykeh J, Menassa J, Mroue’ K, Uthman I, Masri AF, Ghorra P, Witte T, Baraliakos X (2019) HLA-B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study. Int J Rheum Dis. 22:708–714.:https://doi.org/10.1111/1756-185X.13487. Akassou A, Yacoubi H, Jamil A, Dakka N, Amzazi S, Sadki K, Niamane R, Elhassani S, Bakri Y (2015) Prevalence of HLA-B27 in Moroccan healthy subjects and patients with ankylosing spondylitis and mapping construction of several factors influencing AS diagnosis by using multiple correspondence analysis. Rheumatol Int 35:1889–94. https://doi.org/10.1007/s00296-015-3342-x Arévalo M, López-Medina C, Moreno Martinez-Losa M, Moltó A, Font P, Collantes-Estevez E, Gratacós J (2020) Role of HLA-B27 in the comorbidities observed in axial spondyloarthritis: data from COMOSPA. Joint Bone Spine 87:445–448. https://doi.org/10.1016/j.jbspin.2020.03.012 Kısaarslan AP, Sözeri B, Gündüz Z, Zararsız G, Poyrazoğlu H, Düşünsel R (2019) Evaluation of factors affecting the duration of disease-modifying anti-rheumatic drugs application in patients with enthesitis-related arthritis. Eur J Rheumatol 6:130–35. https://doi.org/10.5152/eurjrheum.2019.18180 Soubrier M, Pereira B, Fan A, Frayssac T, Couderc M, Malochet-Guinamand S, Mathieu S, Tatar Z, Tournadre A, Dubost JJ (2018) Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France). Int J Rheum Dis 21:1986–1992. https://doi.org/10.1111/1756-185X.13375 Sebastian A, Wojtala P, Lubiński Ł, Mimier M, Chlebicki A, Wiland P (2017) Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy. Reumatologia 55:157–162. https://doi.org/10.5114/reum.2017.69775 Landewé R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, Marzo-Ortega H, Magrey M, Kiltz U, Wang X, Li M, Zhong S, Mostafa NM, Lertratanakul A, Pangan AL, Anderson JK (2018) Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 392:134–144.: https://doi.org/10.1016/S0140-6736(18)31362-X. Deodhar A, Sandoval D, Holdsworth E, Booth N, Hunter T (2020) Use and switching of biologic therapy in patients with non-radiographic axial spondyloarthritis: a patient and provider survey in the United States. Rheumatol Ther 7:415–423. https://doi.org/10.1007/s40744-020-00208-5 Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72:1149–1155. https://doi.org/10.1136/annrheumdis-2012-201933 Hartung W, Nigg A, Strunk J, Wolff B (2018) Clinical assessment and ultrasonography in the follow-up of enthesitis in patients with spondyloarthritis: a multicenter ultrasound study in daily clinical practice Open Access. Rheumatol 10(161):169. https://doi.org/10.2147/OARRR.S179472 Palominos PE, de Campos APB, Ribeiro SLE, Xavier RM, Xavier JW, de Oliveira FB, Guerra B, Saldanha C, Mancuso ACB, Kohem CL, Gasparin AA, Sampaio-Barros PD (2019) Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a cross-sectional study comparing MASES, SPARCC and LEI. Adv Rheumatol. 59:23.:https://doi.org/10.1186/s42358-019-0066-8. Berg KH, Rohde G, Pripp A, Prøven A, Pirelli Benestad EE, Østensen M, Haugeberg G (2021) Increased proportion of comorbidities but no deterioration of sexual QOL during a 5-year follow-up in patients with axSpA in the biologic treatment era. Rheumatology (Oxford). 7: keaa887.:https://doi.org/10.1093/rheumatology/keaa887 Deodhar A, Yu D (2017) Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum 47:343–350. https://doi.org/10.1016/j.semarthrit.2017.04.005 Lee S, Park YJ, Lee JY (2019) The effect of tumor necrosis factor-alpha inhibitors on uveitis in patients with ankylosing spondylitis. J Korean Med Sci. 4:e278.:https://doi.org/10.3346/jkms.2019.34.e278.